The Global Tennis Elbow Market research

Garner Insights (Market Intelligence and consulting firm)  gave  a  value of  approximately USD 8150.0 million in 2016  and is anticipated to grow with a healthy growth rate of more than 3.20% over the forecast period 2017-2025


Tennis elbow affects 1% to 3% of the population and, overall, 10% to 50% of tennis players during their careers. Fewer than 5% of tennis elbow diagnoses are related to tennis.


Tennis elbow affects men more than women. It most often affects people between the ages of 30 and 50, although people of any age can be affected.


Tennis elbow also affects other athletes and workers who participate in activities that require repetitive arm, elbow and wrist work.

Examples include:

  • Golfers
  • Baseball pitchers
  • Bowlers
  • Garden and lawn workers
  • Jobs that require vacuuming, sweeping, and scrubbing
  • Carpenters and mechanics
  • Assembly line workers

Growth in healthcare investments, prevalence of lateral epicondylitis and growing high-risk geriatric population are the major factors driving the global market growth for lateral epicondylitis treatment. 

North America is the largest regional market at a market share of over 35% in 2015

and the dominance of this region is anticipated to continue through 2022.


Rising incidence of sports injuries and high awareness about treatment and management of tennis elbow together drive the North America lateral epicondylitis market.


Among the treatment types, corticosteroids injections segment is the most prominent market in terms of revenue. However, non-surgical therapies such as platelet rich plasma (PRP), splint elbow brace, ice packs and others will take approximately 40% market share in 2015. 

According to GrandView Research, The overall lateral epicondylitis market is classified on the basis of treatment methods into surgical therapies and non surgical therapies.


The non surgical treatment held the largest market share as of 2014 owing to the efficiency of the treatment without operating the body. The non surgical treatment includes extracorporeal shock wave therapy, braces, medications and physical therapies.


Various anti inflammatory drugs (NSAIDS) such as ibuprofen, aspirin and cortisone are administered to control pain in lateral epicondylitis.


Physical therapies such as muscle stimulation and ice massage are performed to improve healing. Moreover, straps or braces reduce the stress on elbow tendons and muscles.


The very painful extracorporeal shock wave therapy is used for promoting natural healing process in the body. In surgical treatment segment, arthroscopic surgery and open surgery are performed.


The open surgery is expected to witness lucrative growth owing to outpatient surgeries and high success rate of approximately 90-95% and shorter post surgery hospital stay. Various drugs used for treatment of lateral epicondylitis include topical nitrates, botulinum toxin and hyaluronate.


Geographically, the entire lateral epicondylitis market is segmented into North America, Asia Pacific, Europe, Latin America and MEA. As of 2014, North America held the largest market share followed by Europe.  Increasing number of sport events & competitions in the U.S. coupled with increasing patient awareness level are the vital factors for the growth of lateral epicondylitis market in this region. Latin America and Asia regions are anticipated to grow at highest CAGR due to increasing incidences of sport injuries in these regions.


The global lateral epicondylitis market is consolidated in nature. Various companies are striving to gain market share by adopting competitive strategies such as joint ventures and research partnerships. Some key players operating in the market include Teikoku Pharma, Inc., Kasiak Research Pvt. Ltd., Moecular Phramacology Limited, Chugai Pharmaceutical Co., Ltd., and Seikagaku Corporation